Acute severe ulcerative colitis without systemic toxicity: A retrospective multicenter cohort study suggesting refining the definition of acute severe ulcerative colitis [0.03%]
无系统毒性重度溃疡性结肠炎：一项回顾性多中心队列研究，提示应重新定义急性重症溃疡性结肠炎
Frederik Ørtoft,Mathilde Jepsen Nissen,Jens Kjeldsen et al.
Frederik Ørtoft et al.
Background: Acute severe ulcerative colitis (ASUC) is defined by the Truelove and Witts (TW) criteria. However, contemporary practice has shifted toward earlier admission and treatment escalation in advanced therapy-exper...
Persistent Abdominal Pain in Patients with Inactive Inflammatory Bowel Disease: A Clinical Conundrum [0.03%]
炎症性肠病临床缓解期患者的持续腹痛：一个临床难题
Alessandra Dell&#x;Era,Elisabetta Antonelli,Fotios S Fousekis et al.
Alessandra Dell&#x;Era et al.
Background: Gastrointestinal tract inflammation may cause deep alterations of the gut homeostasis, even after the acute phase is resolved. Indeed, there is at present substantial evidence that a considerable percentage of...
Integrated long-term safety of 10-year ozanimod treatment: results from clinical trials in patients with moderate-to-severe ulcerative colitis or relapsing multiple sclerosis [0.03%]
奥扎莫德治疗中重度溃疡性结肠炎或复发型多发性硬化症患者的长期整合安全性：临床试验结果
David T Rubin,Silvio Danese,Hiroshi Nakase et al.
David T Rubin et al.
Background: Ozanimod is a once-daily oral selective sphingosine 1-phosphate receptor modulator approved for the treatment of moderately to severely active ulcerative colitis (UC) or relapsing multiple sclerosis (RMS). Pre...
Safety and outcomes of advanced IBD therapies in patients with HIV: a propensity-matched cohort analysis [0.03%]
人类免疫缺陷病毒感染者使用生物制剂及Janus激酶抑制剂治疗的安全性及其疗效：倾向匹配队列分析
Avneet Kaur,Avleen Kaur,Idan Goren
Avneet Kaur
Importance: Data on advanced therapy (AT) in patients with HIV and inflammatory bowel disease (HIV-IBD) are limited. Objective We evaluated the safety and outcomes of AT in this population using real-world data. ...
Advanced therapies for inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and meta-analysis [0.03%]
与原发性硬化性胆管炎相关炎症性肠病的先进疗法：系统评价和荟萃分析
Darrick K Li,Abdelkader Chaar,Tarek Arabi et al.
Darrick K Li et al.
Background and aims: Up to 70%-80% of patients with primary sclerosing cholangitis (PSC) will have concomitant inflammatory bowel disease (IBD). Scarce data are available regarding outcomes of advanced therapies to treat ...
Nomenclature of therapies in inflammatory bowel disease: A journey through time and terminology [0.03%]
炎症性肠病治疗术语的演变：穿越时空与语言的历史之旅
Michael Colwill,Kamal Patel,Shaji Sebastian et al.
Michael Colwill et al.
The expanding therapeutic landscape of inflammatory bowel disease has highlighted the need for clear and standardized drug nomenclature to support safe prescribing, pharmacovigilance, international communication, and patient understanding. ...
Primary infliximab failure in pediatric colonic inflammatory bowel disease: Development of a proteomics predictive model using a prospective Canadian cohort [0.03%]
使用前瞻性加拿大队列开发蛋白质组学预测模型以预测儿科结肠炎性肠病患者对英夫利昔单抗原发失效
Amanda Ricciuto,Andrei L Turinsky,Anne M Griffiths et al.
Amanda Ricciuto et al.
Background: We aimed to build a serum proteomics-based model to predict primary nonresponse (PNR) to infliximab (IFX) in pediatric colonic inflammatory bowel disease, with early proactive therapeutic drug monitoring. ...
Stricture dynamics and prognosis during biologic therapy in ileal Crohn's disease: a real-world cohort [0.03%]
真实世界克罗恩病队列中类克治疗期间回肠狭窄的动态变化及预后研究
Kento Takenaka,Ami Kawamoto,Shuji Hibiya et al.
Kento Takenaka et al.
Background and aims: Clinicians need data on the responsiveness of ileal strictures of Crohn's disease (CD) to biologic therapy, yet most trials prioritize mucosal healing. We quantified short‑term changes in ileal stric...
Immunometabolism as a New Bimodal Therapeutic Concept in Inflammatory Bowel Disease and Immune-Mediated Inflammatory Disorders [0.03%]
免疫代谢作为炎症性肠病和免疫介导的炎性疾病中新的双向治疗概念
Virginia Solitano,Laurent Peyrin-Biroulet,Severine Vermeire et al.
Virginia Solitano et al.
Immunometabolism exerts a bimodal action at the interface of extracellular immune response and intracellular metabolism, putting it at the center of many immune-mediated inflammatory disorders (IMIDs). Research has shown that immunometaboli...
Rapid symptomatic improvement with etrasimod in ulcerative colitis: a post-hoc analysis of the ELEVATE UC program [0.03%]
ELEVATE UC研究事后分析：Etrasimod治疗溃疡性结肠炎可快速改善症状
Marla C Dubinsky,María Chaparro,Peter M Irving et al.
Marla C Dubinsky et al.
Introduction: Rapid symptom relief is an important consideration for patients with ulcerative colitis (UC) experiencing a flare. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator ...